百奥泰：创新药重组抗VEGF人源化单克隆抗体注射液（BAT5906）获临床试验批准

Core Viewpoint - The company Baiotai (688177.SH) has received approval from the National Medical Products Administration for clinical trials of its drug BAT5906, targeting additional indications for retinal central vein occlusion-related macular edema and pathological myopia-related choroidal neovascularization [2] Group 1: Drug Approval and Indications - BAT5906 has been approved for clinical trials for multiple indications, including wet age-related macular degeneration (w-AMD), diabetic macular edema (DME), central retinal vein occlusion-related macular edema (CRVO-ME), and pathological myopia-related choroidal neovascularization (pmCNV) [2] - The company has completed Phase I, II, and III clinical studies for the w-AMD indication, and Phase II clinical studies for the DME indication, while CRVO-ME and pmCNV are in the preparation stage for Phase II/III clinical studies [2]